tiprankstipranks
Trending News
More News >

Nxera Pharma Secures $4.8 Million Milestone Payment from Centessa

Story Highlights
Nxera Pharma Secures $4.8 Million Milestone Payment from Centessa

Don’t Miss TipRanks’ Half-Year Sale

Sosei Group ( (JP:4565) ) just unveiled an update.

Nxera Pharma announced it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals following the initiation of clinical development for ORX142, a novel orexin receptor 2 agonist. This development marks a significant step in the treatment of neurological and neurodegenerative disorders, with the revenue from these milestones recognized in the second and third quarters of 2025. The collaboration underscores Nxera’s strategic partnerships and its impact on advancing treatments in high-growth medical areas.

The most recent analyst rating on (JP:4565) stock is a Buy with a Yen2000.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.

More about Sosei Group

Nxera Pharma is a technology-powered biopharmaceutical company focused on developing and commercializing innovative specialty medicines to address unmet medical needs in Japan and globally. The company leverages its NxWave™ discovery platform to advance a pipeline of over 30 active programs targeting neurology, neuropsychiatry, metabolic diseases, and immunology and inflammation. Nxera operates in key locations across Japan, the UK, Switzerland, and South Korea and is listed on the Tokyo Stock Exchange.

Average Trading Volume: 927,477

Technical Sentiment Signal: Sell

Current Market Cap: Yen80B

For a thorough assessment of 4565 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1